Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Related Questions
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
Which anticoagulant (DOAC or Warfarin) would you recommend in the case of a 70-year-old male with persistent atrial fibrillation and history of rheumatic mitral stenosis now status post bioprosthetic MVR?
How long should patients with atrial fibrillation who are already on systemic anticoagulation and are status post TAVR and PCI 6 months ago remain on Plavix?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
What is your approach to the management of severe tricuspid regurgitation secondary to endocarditis with the presence of an RV pacemaker lead in place?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
What is the optimal anti-platelet/anticoagulant strategy and duration following a left atrial appendage occlusion with a watchmen device and is a CTA good enough to assess if the device is well seated and without any peri device leaks?
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
What is your preferred single antiplatelet agent to use when combined with a DOAC for a patient with atrial fibrillation who is now 1 year post-TAVR?
